We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$217M
Cap. Flow %
4.4%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.59%
2 Miscellaneous 8.92%
3 Financials 0.49%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.05T
$326M 6.62%
1,007,000
+397,000
+65% +$126M
XNTK icon
2
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$321M 6.53%
+4,052,000
New +$441M
UTHR icon
3
United Therapeutics
UTHR
$22.1B
$203M 4.13%
970,200
+244,600
+34% +$54.7M
NBIX icon
4
Neurocrine Biosciences
NBIX
$15.7B
$197M 4.01%
1,855,700
+388,100
+26% +$39.4M
ARVN icon
5
Arvinas
ARVN
$600M
$193M 3.93%
4,343,500
+987,877
+29% +$48M
ARGX icon
6
argenx
ARGX
$64B
$174M 3.53%
491,800
-80,700
-14% -$29.9M
BIIB icon
7
Biogen
BIIB
$32.3B
$160M 3.26%
600,000
+159,434
+36% +$33.9M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$137B
$148M 3.02%
512,800
-280,200
-35% -$80.6M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.74B
$134M 2.73%
5,586,900
+136,900
+3% +$3.07M
PRTA icon
10
Prothena Corp
PRTA
$479M
$119M 2.42%
+1,967,000
New +$62.2M
XBI icon
11
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$117M 2.39%
1,480,000
-395,000
-21% -$33.3M
ACHC icon
12
Acadia Healthcare
ACHC
$2.66B
$109M 2.21%
1,389,200
+354,200
+34% +$28.3M
AKRO
13
DELISTED
Akero Therapeutics
AKRO
$106M 2.16%
+3,122,000
New +$47.8M
SRPT icon
14
Sarepta Therapeutics
SRPT
$2.2B
$105M 2.13%
+948,200
New +$95.6M
HUM icon
15
Humana
HUM
$46.3B
$103M 2.09%
212,000
-200,300
-49% -$97.4M
BSX icon
16
Boston Scientific
BSX
$67.9B
$98.3M 2%
2,538,600
+13,600
+0.5% +$546K
IMCR icon
17
Immunocore
IMCR
$1.89B
$97.6M 1.98%
2,079,100
+729,100
+54% +$34.7M
KRTX
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$97.1M 1.97%
431,800
+227,230
+111% +$46M
ELV icon
19
Elevance Health
ELV
$85.5B
$94.3M 1.92%
207,600
-233,400
-53% -$112M
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$91.7M 1.87%
1,482,200
-374,700
-20% -$26.2M
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$360M
$91.5M 1.86%
4,223,100
+637,219
+18% +$17.4M
AVTR icon
22
Avantor
AVTR
$9.86B
$88.6M 1.8%
4,522,600
-2,130,100
-32% -$57.1M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.52B
$85M 1.73%
2,051,600
+572,100
+39% +$29.4M
NTRA icon
24
Natera
NTRA
$47B
$76M 1.55%
1,735,000
+365,900
+27% +$17.4M
AXSM icon
25
Axsome Therapeutics
AXSM
$10.4B
$68.7M 1.4%
+1,538,600
New +$76.9M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $217M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.